KRAS and neoplasm: The activity and selectivity of FGFR/PLK1 inhibitors as a synergistic combination treatment (Lehár et al, 2009), which is restricted to KRAS‐mutant lung and pancreatic but not colon cancer cells, were validated in multiple in vitro and in vivo tumor models (e.g., GEMM and PDXs) and further supported by genetic evidence whereby RNAi‐based co‐depletion of PLK1/FGFR1 drives massive tumor cell death.